Portal de investigación
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
SUMITOMO PHARMA AMERICA, INC.
Cita
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation. (DSP-5336-101). SUMITOMO PHARMA AMERICA, INC. 2023IP:PAU MONTESINOS FERNÁNDEZ.